Resource Center
Always with a focus on innovation, find resources that share our scientific experts passion and knowledge. Find case studies, info sheets, posters and more.
Global Approaches to Oral Drug Administration Using Enteral Feeding Tubes: A Review of FDA and EMA Guidance
Download81 - 90 of 230 results
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial
3 May 2022A First-in-Human (FIH) Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses, and Alternative Formulations of R941552 (R552): A selective Receptor Interacting Protein 1 (RIP1) Kinase Inhibitor
24 March 2022A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors
15 March 2022Absolute Bioavailability, Mass Balance, and Metabolic Profiling Assessment of [14C]-Belumosudil in Healthy Men: A Phase 1, Open-Label, 2-Part Study
15 March 2022ACCP: A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors
7 March 2022Astrazeneca - Characterization of Clinical ADME & Pharmacokinetics of Velsecorat Using an IV Microtracer Combined with an Inhaled Dose in Healthy Subjects
2 February 2022Development of a Once‑Daily Modified‑Release Formulation for the Short Half‑Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology
10 January 2022Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects
3 January 2022An integrated radiolabelled study to determine the mass balance, metabolite profile and identification, and absolute bioavailability of nolasiban in healthy female subjects
22 December 2021Influence of drug loading and fillers on drug release from HPMC matrix tablets
22 December 2021Learn more about Quotient Sciences' services
See how we can help you with your next drug program.